VivoSim Labs, Inc. (VIVS) Balance Sheet

NASDAQ: VIVSAssets, liabilities, debt and equity over 10 years.

VIVS balance sheet, FY2026

March 31, 2026 · U.S. dollars

$7.4M assets = $8.5M liabilities + −$1.1M equity

What it owns$7.4MCash & ST investments: $5.0M (68.0%)Cash & ST investments$5.0M · 68%Receivables: $1.0M (14.2%)Receivables$1.0M · 14%Other current: $557,000 (7.5%)Other current $557,000PP&E: $613,000 (8.3%)PP&E $613,000Other non-current: $146,000 (2.0%)=How it is financed$8.5MCurrent liabilities: $2.8M (32.8%)Current liabilities$2.8M · 33%Other LT liabilities: $5.7M (67.2%)Other LT liabilities$5.7M · 67%

Liabilities exceed assets: shareholders’ equity is negative (−$1.1M).

Both columns are drawn to the same scale: what VIVS owns equals what it owes plus shareholders’ equity. Hover a block for its value.

VIVS financial health

Current ratio2.38
Comfortable · current assets cover current liabilities 2.38×
Equity / assets−14.9%
Thin equity · of assets funded by shareholders
Cash / debt1,123.9%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal FY2026.

VIVS balance sheet trends, FY2017–FY2026

VivoSim Labs, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$69.2MFY2017$7.4MFY2026−22.0%/yr
Total liabilities$6.8MFY2017$8.5MFY2026+2.5%/yr
Shareholders’ equity$62.4MFY2017−$1.1MFY2026—
Cash & short-term investments$62.8MFY2017$5.0MFY2026−24.5%/yr
Total debt$2.2MFY2022$447,000FY2026−32.7%/yr
Net cash (debt)$26.5MFY2022$4.6MFY2026−$21.9M
Working capital$59.1MFY2017$3.8MFY2026−$55.2M
Current ratio10.83FY20172.38FY2026−8.45
Debt / equity0.07FY20220.09FY2025+0.02

Change is the average annual growth (CAGR) or the difference between the first and latest year.

VIVS assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

VIVS liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

VIVS debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

VIVS balance sheet

VivoSim Labs, Inc. annual balance sheet
FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Assets
Cash & short-term investments$5.0M$11.3M$2.9M$16.0M$28.7M$37.4M$27.4M$36.5M$43.7M$62.8M
Cash & equivalents$5.0M$11.3M$2.9M$15.3M$28.7M$37.4M$27.4M$36.5M$43.7M$62.8M
Short-term investments——$0$706,000$0—————
Receivables$1.0M$30,000$33,000$152,000$0$0$111,000$558,000$1.0M$647,000
Inventory$0$0$297,000$0$0$0$0$490,000$842,000$550,000
Other current assets$557,000$789,000$705,000$889,000$858,000$1.0M$851,000$1.0M$1.2M$1.1M
Total current assets$6.6M$12.1M$3.9M$17.0M$29.5M$38.4M$28.3M$38.6M$46.8M$65.1M
Property, plant & equipment (net)$613,000$1.3M$2.0M$2.6M$2.8M$381,000$0$1.8M$2.8M$3.8M
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$146,000$1.2M$445,000$658,000$948,000$1.1M$123,000$217,000$279,000$248,000
Total assets$7.4M$14.7M$6.3M$20.3M$33.3M$39.9M$28.4M$40.6M$49.8M$69.2M
Liabilities
Accounts payable$1.0M$1.6M$627,000$331,000$415,000$281,000$720,000$628,000$464,000$1.2M
Short-term debt$447,000$521,000$506,000$492,000$479,000—————
Deferred revenue———————$525,000$668,000$582,000
Total current liabilities$2.8M$3.7M$1.9M$3.7M$1.4M$721,000$1.8M$3.7M$4.7M$6.0M
Long-term debt$0$0$0$0$0$0$0$0$0$0
Lease obligations$447,000$942,000$1.4M$1.8M$2.2M$0————
Other long-term liabilities$5.7M$421,000$888,000$1.3M$1.7M$0$0$588,000$583,000$807,000
Total liabilities$8.5M$4.2M$2.7M$5.0M$3.1M$721,000$1.8M$4.3M$5.2M$6.8M
Shareholders' equity
Common stock & paid-in capital$3,000$2,000$10,000$9,000$9,000$9,000$7,000$124,000$111,000$104,000
Retained earnings (deficit)−$356.0M−$342.2M−$339.7M−$325.0M−$307.7M−$296.3M−$279.5M−$260.8M−$234.1M−$199.3M
Accumulated other comprehensive income———$2,000—————−$11,000
Total shareholders' equity−$1.1M$10.5M$3.6M$15.3M$30.2M$39.2M$26.6M$36.3M$44.6M$62.4M
Key figures
Total debt$447,000$942,000$1.4M$1.8M$2.2M—————
Net cash (debt)$4.6M$10.4M$1.5M$14.2M$26.5M—————
Working capital$3.8M$8.4M$2.1M$13.4M$28.1M$37.7M$26.5M$34.8M$42.1M$59.1M
Tangible book value−$1.1M$10.5M$3.6M$15.3M$30.2M$39.2M$26.6M$36.3M$44.6M$62.4M
Current ratio2.383.252.124.6421.3553.2615.6510.3210.0410.83
Quick ratio2.183.041.584.4020.7351.8215.189.919.6110.55
Debt / equity—0.090.390.120.07—————
Equity / assets−14.9%71.6%56.7%75.5%90.7%98.2%93.6%89.4%89.5%90.1%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed July 14, 2026); data from EODHD.

VIVS financial position

At the end of fiscal 2026 (March 31, 2026), VivoSim Labs had total assets of $7.4 million (down 49.6% from a year earlier), total liabilities of $8.5 million and shareholders' equity of -$1.1 million. It held $5.0 million in cash and short-term investments against $0.4 million of debt, a net cash position of $4.6 million. Its current ratio was 2.38. In the latest quarter (ended June 30, 2026) total assets were $3.8 million and equity -$2.3 million.

Related: VIVS income statement, VIVS cash flow statement, VIVS key metrics. See the VIVS stock overview for the latest quote and news.

VIVS balance sheet FAQ

What are VivoSim Labs's total assets?

VivoSim Labs reported total assets of $7.4 million at the end of fiscal 2026 (March 31, 2026), compared with $14.7 million a year earlier.

How much debt does VivoSim Labs have?

VivoSim Labs had $0.4 million of total debt at the end of fiscal 2026, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.

How much cash does VivoSim Labs have?

VivoSim Labs held $5.0 million in cash and short-term investments at the end of fiscal 2026; with $0.4 million of debt that is net cash of $4.6 million.

What is VivoSim Labs's book value?

VivoSim Labs's shareholders' equity (book value) was -$1.1 million at the end of fiscal 2026.

What is VivoSim Labs's current ratio?

VivoSim Labs had current assets of $6.6 million and current liabilities of $2.8 million, a current ratio of 2.38 (it can cover its short-term obligations).

Biotechnology: balance sheet